- Home
- XRTX vs PHIO Comparison
XRTX vs PHIO Comparison
Compare XRTX & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XRTX
- PHIO
- Stock Information
- Founded
- XRTX 2011
- PHIO 2011
- Country
- XRTX Canada
- PHIO United States
- Employees
- XRTX N/A
- PHIO N/A
- Industry
- XRTX Pharmaceuticals and Biotechnology
- PHIO Biotechnology: Pharmaceutical Preparations
- Sector
- XRTX Health Care
- PHIO Health Care
- Exchange
- XRTX Nasdaq
- PHIO Nasdaq
- Market Cap
- XRTX 3.0M
- PHIO 6.2M
- IPO Year
- XRTX N/A
- PHIO N/A
- Fundamental
- Price
- XRTX $0.92
- PHIO $1.34
- Analyst Decision
- XRTX
- PHIO Strong Buy
- Analyst Count
- XRTX 0
- PHIO 1
- Target Price
- XRTX N/A
- PHIO $4.00
- AVG Volume (30 Days)
- XRTX 84.2K
- PHIO 162.7K
- Earning Date
- XRTX 05-09-2025
- PHIO 05-08-2025
- Dividend Yield
- XRTX N/A
- PHIO N/A
- EPS Growth
- XRTX N/A
- PHIO N/A
- EPS
- XRTX N/A
- PHIO N/A
- Revenue
- XRTX N/A
- PHIO N/A
- Revenue This Year
- XRTX N/A
- PHIO N/A
- Revenue Next Year
- XRTX N/A
- PHIO N/A
- P/E Ratio
- XRTX N/A
- PHIO N/A
- Revenue Growth
- XRTX N/A
- PHIO N/A
- 52 Week Low
- XRTX $0.82
- PHIO $1.22
- 52 Week High
- XRTX $5.81
- PHIO $9.99
- Technical
- Relative Strength Index (RSI)
- XRTX 42.89
- PHIO 36.73
- Support Level
- XRTX $0.85
- PHIO $1.26
- Resistance Level
- XRTX $1.10
- PHIO $1.44
- Average True Range (ATR)
- XRTX 0.11
- PHIO 0.10
- MACD
- XRTX 0.00
- PHIO 0.01
- Stochastic Oscillator
- XRTX 11.63
- PHIO 15.92
About XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.